ALK og Novozymes indgår aftale om fremtidige allergivacciner
February 23, 2009 04:36 ET
|
ALK Abello
ALK og Novozymes har i dag underskrevet en aftale om produktion af industrielt
fremstillede allergener, også kaldet rekombinante allergener, til brug i ALKs
fremtidige tabletbaserede...
ALK and Novozymes enter collaboration on future allergy vaccines
February 23, 2009 04:36 ET
|
ALK Abello
Today, ALK and Novozymes have signed an agreement regarding industrially
produced allergens, also called recombinant allergens, for use in ALK's future
allergy immunotherapy tablets.
Under the...
ALK announces annual report for 2008
February 19, 2009 07:58 ET
|
ALK Abello
For ALK, 2008 was a good year with breakthrough research results and
satisfactory financial results. ALK met its financial forecast and generated a
five-fold increase of the underlying operating...
ALK offentliggør årsrapport for 2008
February 19, 2009 07:58 ET
|
ALK Abello
For ALK blev 2008 et godt år med banebrydende forskningsresultater og
tilfredsstillende økonomiske resultater. ALK indfriede sine økonomiske
forventninger og realiserede en femdobling af den...
Shareholder announcement
February 06, 2009 03:18 ET
|
ALK Abello
Pursuant to section 28(a) of the Danish Public Companies Act and section 29 of
the Danish Securities Trading Act, ALK has received notification from ATP (the
Danish Labour Market Supplementary...
Ejermeddelelse
February 06, 2009 03:18 ET
|
ALK Abello
I henhold til Aktieselskabslovens § 28a og Værdipapirhandelslovens § 29 har ALK
modtaget meddelelse fra ATP om, at ATP og ATP Invest, Hillerød, efter salg har
nedbragt deres ejerandele i ALK-Abelló...
Release date of annual report 2008 for ALK and analyst meeting
February 05, 2009 09:15 ET
|
ALK Abello
ALK releases its annual report 2008 on Thursday, February 19, 2009.
The company therefore invites analysts and investors to a meeting with
Management on Friday, February 20, at 09.00 a.m. at the...
Dato for offentliggørelse af årsrapport 2008 for ALK og analytikermøde
February 05, 2009 09:15 ET
|
ALK Abello
ALK offentliggør årsrapport for 2008 torsdag den 19. februar 2009.
I den forbindelse inviteres analytikere og investorer til møde fredag den 20.
februar kl.09.00 på selskabets adresse, Bøge Allé...
ALK køber aktier i den franske virksomhed DBV Technologies
January 22, 2009 02:01 ET
|
ALK Abello
Resume: ALK investerer i udvikling af vaccine mod peanutallergi
ALK har indgået aftale om at investere 2 mio. EUR i den franske
biotekvirksomhed DBV Technologies som en del af en opfølgende...
ALK acquires shares in DBV Technologies, France
January 22, 2009 02:01 ET
|
ALK Abello
Summary: ALK invests in development of a peanut allergy vaccine
ALK has signed an agreement to invest EUR 2 million in the French biotech
company DBV Technologies as part of a follow-up equity...